Wen et al[26] and Su et al[27] focused on the cost-effectiveness of an ICI plus a VEGF inhibitor vs. a tyrosine kinase inhibitor (atezolizumab plus bevacizumab vs. sorafenib) for the treatment of advanced HCC in China. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.